Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 1214Neoplasms 1024Carcinoma, Non-Small-Cell Lung 851Prostatic Neoplasms 683Colorectal Neoplasms 608Lung Neoplasms 575Neoplasm Metastasis 431Multiple Myeloma 420Leukemia, Myeloid, Acute 394Pancreatic Neoplasms 371Ovarian Neoplasms 359Melanoma 317Carcinoma, Hepatocellular 284Recurrence 274Squamous Cell Carcinoma of Head and Neck 272Brain Neoplasms 264Glioblastoma 245Head and Neck Neoplasms 241Stomach Neoplasms 236Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Carcinoma, Renal Cell 225Lymphoma 221Triple Negative Breast Neoplasms 216Endometrial Neoplasms 207Hematologic Neoplasms 206Urinary Bladder Neoplasms 195Lymphoma, Non-Hodgkin 194Sarcoma 189Uterine Cervical Neoplasms 187Glioma 187

Interventions

relacorilant 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Diseases × 90 days × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡